Why the study?
Persons with severe mental illness have reduced life expectancy and are disproportionately affected by cardiovascular disorders, requiring a better understanding of factors influencing cardiovascular risk management.
A co-designed health promotion program aims to empower persons with severe mental illness to better manage their cardiovascular risk, with future evaluation planned via a randomized controlled trial.
Identifies barriers/facilitators for CV risk management in SMI; leaves open need for interventional trials before practice change.
BACKGROUND: Persons with a diagnosis of severe mental illness have a life expectancy that is 20 years lower than the general population, and they are disproportionately affected by cardiovascular disorders. Improving the management of cardiovascular risk is one of the main challenges for the public health system. In the care pathway of persons with a diagnosis of severe mental illness, a better understanding of limiting and facilitating factors is required. The objective was to include persons with a diagnosis of severe mental illness, carers, and primary and mental health professionals in the creation and evaluation (feasibility) of a health promotion program designed to improve cardiovascular risk management through empowerment. METHODS: This study combines a mixed methodology with qualitative and quantitative components. A multicenter prospective qualitative study was conducted in seven mental health units in France and was coordinated by a steering committee composed of persons with a diagnosis of severe mental illness, carers, and primary and mental health professionals. RESULTS: This health promotion program must enable persons with a diagnosis of severe mental illness to assert their right to self-determination and to exercise greater control over their lives, beyond their diagnosis and care. Following a preliminary feasibility study, the effectiveness of this new tool will be evaluated using a randomized controlled trial in a second study. CONCLUSIONS: Clinical Trials Gov NCT03689296. Date registered September 28, 2018.
No takes yet. Share an insight, caveat, or question.
Baleige et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: